Abstract
IntroductionUnderstanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors. In this survey, we quantified the relative preferences among patients in Germany and Spain in separate analyses.MethodsA stated-preference, discrete-choice experiment (DCE) survey was designed to elicit preferences for T2DM treatment attributes among patients with self-reported T2DM and who reported being prescribed T2DM medication for > 2 years. Patients recruited from an online national consumer panel completed an online survey. The survey presented choices between eight pairs of hypothetical T2DM treatments defined by seven attributes: chance of reaching target hemoglobin A1c (HbA1c) level; reduced risk of serious heart attack or stroke; frequency of hypoglycemia; risk of gastrointestinal (GI) problems; weight change; mode of administration (oral or injectable); dosing frequency. Data were analyzed using random-parameters logit. Minimum acceptable benefit (MAB) was defined as the minimum increase in the probability of reaching target HbA1c for which respondents would accept less desirable levels of other attributes.ResultsIn Germany and Spain, 474 and 401 respondents completed the survey, respectively. DCE analysis showed that risk of GI problems was most important to German respondents. MAB analysis found that respondents would require a 56 percentage point increase in the probability of reaching their HbA1c target to offset a change from 0% to 30% risk of GI problems. For Spanish respondents, mode of administration was the most important attribute. These respondents would require a 59 percentage point increase in the probability of reaching their HbA1c target to offset moving from oral to injectable medications.ConclusionsRespondents in Germany and Spain were willing to trade efficacy for improvements in side effects and mode of administration. Given the variety of T2DM medications currently available, the results suggest that careful discussion about patient preferences could help improve patient satisfaction with T2DM treatment.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-017-0326-8) contains supplementary material, which is available to authorized users.
Highlights
Understanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors
Given the variety of T2DM medications currently available, the results suggest that careful discussion about patient preferences could help improve patient satisfaction with T2DM treatment
The discrete-choice experiments (DCEs) questions posed a choice between two hypothetical treatments for T2DM, with each treatment being defined by a set of seven attributes at varying levels: (1) the chance of achieving the respondent’s hemoglobin A1c (HbA1c) target; (2) reduced risk of serious heart attack or stroke; (3) frequency of hypoglycemic events; (4) risk of gastrointestinal (GI) problems; (5) changes in body weight; (6) mode of administration; (7) frequency of dosing (Table 1)
Summary
Understanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors. In this survey, we Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 0BCCF0603FFD36A6. The basis for DCEs is the principle that products comprise a set of attributes and that the value of a product to an individual is a function of these attributes [12] This approach provides information on people’s willingness to accept tradeoffs between features of multi-attribute products, recognizing that individuals place different levels of importance on different product attributes [13]. The primary objective of the study reported here was to quantify preferences for attributes of T2DM treatments among patients with T2DM in Germany and Spain using a DCE survey
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
